ClinicalTrials.gov
public full text
Public Domain
Lenalidomide and Obinutuzumab for Previously Untreated CLL
This is phase 1/2 study for patients with CLL or (SLL) who have not been previously treated. This study will evaluate whether obinutuzumab and lenalidomide is safe and tolerable in this setting and induce complete clinical responses.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy#1369309
- Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL#287527
- Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)#1087822
- Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL#1365741
- Lenalidomide in Patients With Chronic Myelomonocytic Leukemia#889222
Record · ID 1214132
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive